Alkermes Plc  

(Public, NASDAQ:ALKS)   Watch this stock  
Find more results for ALKS
50.54
0.00 (0.00%)
Sep 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 41.93 - 63.40
Open     -
Vol / Avg. 0.00/706,729.00
Mkt cap 7.77B
P/E     -
Div/yield     -
EPS -1.28
Shares 153.65M
Beta 2.23
Inst. own 102%
Oct 31, 2017
Q3 2017 Alkermes Plc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 11, 2017
Alkermes Plc at Morgan Stanley Healthcare Conference - Webcast
Jul 27, 2017
Q2 2017 Alkermes Plc Earnings Release
Jul 27, 2017
Q2 2017 Alkermes Plc Earnings Call
Jun 29, 2017
Alkermes Plc to Discuss ENLIGHTEN-1 ALKS 3831 Data
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -19.65% -27.95%
Operating margin -20.34% -27.98%
EBITD margin - -15.34%
Return on average assets -9.97% -11.64%
Return on average equity -14.26% -16.52%
Employees 1,750 -
CDP Score - -

Address

Connaught HSE, 1 Burlington Road
DUBLIN, MA 00000
Ireland
+353-1-7728000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Officers and directors

Richard F. Pops Chairman, President, and CEO
James M. (Jim) Frates SVP, CFO, and Treasurer
Gordon G. Pugh SVP, COO, and Chief Risk Officer
Richard F. Pops Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shane M. Cooke President
Age: 54
Bio & Compensation  - Reuters
James M. Frates Chief Financial Officer, Senior Vice President, Treasurer
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kathryn L. Biberstein Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Chief Risk Officer, Secretary
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Elliot W. Ehrich M.D. Executive Vice President - Research and Development and Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Iain M. Brown Senior Vice President - Finance, Chief Accounting Officer
Age: 48
Bio & Compensation  - Reuters
David Joseph Gaffin Senior Vice President, Chief Legal Officer
Age: 45
Bio & Compensation  - Reuters